BAXTER INTERNATIONAL INC acquires PerClot Polysaccharide Hemostatic System (assets, from CryoLife, Inc.)

BAXTER INTERNATIONAL INC acquired PerClot Polysaccharide Hemostatic System (assets, from CryoLife, Inc.) for $25 million upfront cash plus up to $36 million of additional contingent consideration (acquisition-date fair value $28 million), a transaction completed in July 2021, structured as all cash (with contingent consideration). The deal was a Asset purchase.

PerClot Polysaccharide Hemostatic System (assets, from CryoLife, Inc.) operates in BioSurgery / hemostats, is based in Acquired from CryoLife, Inc. (Kennesaw, Georgia, USA); distribution rights for the U.S. and specified ex-US territories. PerClot Polysaccharide Hemostatic System is an absorbable powder hemostat; Baxter acquired certain related assets, including distribution rights for the U.S. and specified territories outside the U.S., from CryoLife, Inc.

Adds a complementary absorbable hemostat to Baxter's biosurgery and advanced surgery portfolio.

Complementary absorbable hemostat extending Baxter's BioSurgery / Advanced Surgery franchise. Integrated into Baxter's Advanced Surgery business